Seald AS is a biotech company developing an innovative live and personalised medical diagnostic for treating solid cancer.

As each patient is unique, so is their cancer. The method is an advanced decision tool based on treatment of patients own live cancer cells that aims to identify the best cancer drug in the optimal dose for each individual, avoiding non-effective cancer treatment which potentially only adds side effects.

Investigations reveal that most cancer drugs do not lead to beneficial treatment effect for several of the cancer patients treated with the drug. These groups of none-responders lack a diagnostic method that reveals which drug to take and which to avoid. Treating individual non-responders with ineffective cancer drug is troublesome from an ethical perspective. For society, facing 20 Mn new cancer patients yearly, treating non-responders is costly, non-effective and lacks sustainability.

Our first disease model bile duct cancer, cholangiocarcinoma, is a very deadly form of cancer. The five year survival is two to five per cent, the mean life expectancy on standard chemotherapy is only 11,5 months. A small number of patients are eligible for surgery, and more than 50 per cent of these relapse. There is  a huge unmet medical need for our diagnostic that pinpoints the right patient to the right drug.

Welcome to Seald AS

Addressing uncertainty. Unravelling cures.

Seald AS is a biotech company developing an innovative personalised diagnostic approach for treating solid cancers. Utilising a whole new approach, we aspire to find the right treatment for the individual patient based on a methodology combining ex-vivo drug sensitivity analysis on patient own live cancer cells, molecular biomarkers, DNA sequencing and xenograft models.
Our first disease model, bile duct cancer, is a very deadly form of cancer afflicting three per cent of people with cancer in the digestive system. Together with our research partners Institute of Cancer Research, The Radium Hospital, Seald plan to run the first clinical study at the renowned Norwegian Radium Hospital.


Renowned partners

Recognised scientific actors on board

Innovative approach

To quickly identify effective treatment using evidence-based tests using the patients own living cancer cells.

Unmet medical need

The traditional approach to cancer treatment is based on which organ is afflicted. Personalised treatment also takes into account specific molecular deviations in the tumour before selecting the cancer drug.
Many patients do not benefit the drug and are treated with therapies that do not work.

Large, global market

There were 20 Mn new cases of cancer worldwide (2019). As  70% increase in the number of cancer patients is expected over the coming 20 years, health expenditure on cancer increases continuously.

The global cancer treatment marked is $135 Bn, whereof the tumour profiling marked is $ 7.5 Bn (2018/19).
Theses numbers imply a non-sustainable and increasing cost of treating of non-responders.


Clinical trial approved by the Norwegian Committee for Medical and Health Research Ethics

Clinical development will be conducted in collaboration with both Norwegian and American clinical research centres, and will be succeeded with an interventional study. These trials will be conducted at the Clinical Cancer Research Unit (Phase I unit) at the Norwegian Radium Hospital, Oslo University Hospital.

New innovative therapies for bile duct cancer

In developing of our dynamic technology, and by using bile duct cancer as our first disease model, we revealed remarkable effects of new cancer drugs not previously been available for this diagnosis. This effects were discovered by employing a multidisciplinary approach to developing completely personalised cures, through unraveling both new diagnostics, medications and a new method for personalised targeted treatments. As standard medical treatment today is a combination of generic chemotherapy, with mean survival 11,5 months, these patients are in great need of more effective cancer drugs.

Seald has received grant from

Our Research Partners